Literature DB >> 7036765

Sulfadoxine-pyrimethamine for the treatment of acute malaria in children of Papua New Guinea. II. Plasmodium vivax.

B Darlow, H Vrbova, S Gibney, D Jolley, J Stace, M Alpers.   

Abstract

In Papua New Guinea, Plasmodium falciparum and P. vivax are common causes of acute malaria in children and P. malariae an uncommon cause. The increasing prevelance of chloroquine-resistant strains of P. falciparum in Papua New Guinea has prompted the search for alternatives to chloroquine as standard presumptive treatment. Sulfadoxine-pyrimethamine, either alone or in combination with a single dose of chloroquine, was compared with chloroquine alone for treatment of acute vivax malaria in children in Madang. Fever resolution was slowest in the group treated with sulfadoxine-pyrimethamine alone, and time to clearance of parasitemia was significantly longer in this group (P less than 0.001). Where possible, species identification should be undertaken in acute malaria and cases of P. vivax treated with chloroquine.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7036765     DOI: 10.4269/ajtmh.1982.31.10

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  10 in total

Review 1.  Antimalarial agents: specific treatment regimens.

Authors:  D J Krogstad; B L Herwaldt; P H Schlesinger
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

Review 2.  Plasmodium vivax treatments: what are we looking for?

Authors:  Ric N Price; Nicholas M Douglas; Nicholas M Anstey; Lorenz von Seidlein
Journal:  Curr Opin Infect Dis       Date:  2011-12       Impact factor: 4.915

3.  Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations.

Authors:  Emiliana Tjitra; Joanne Baker; Sri Suprianto; Qin Cheng; Nicholas M Anstey
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

4.  Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system.

Authors:  Alyson M Auliff; John H Adams; Michael T O'Neil; Qin Cheng
Journal:  Antimicrob Agents Chemother       Date:  2010-06-21       Impact factor: 5.191

Review 5.  Vivax malaria: neglected and not benign.

Authors:  Ric N Price; Emiliana Tjitra; Carlos A Guerra; Shunmay Yeung; Nicholas J White; Nicholas M Anstey
Journal:  Am J Trop Med Hyg       Date:  2007-12       Impact factor: 2.345

6.  Sulfadoxine resistance in Plasmodium vivax is associated with a specific amino acid in dihydropteroate synthase at the putative sulfadoxine-binding site.

Authors:  Michael Korsinczky; Katja Fischer; Nanhua Chen; Joanne Baker; Karl Rieckmann; Qin Cheng
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

7.  Multiplicity and diversity of Plasmodium vivax infections in a highly endemic region in Papua New Guinea.

Authors:  Cristian Koepfli; Amanda Ross; Benson Kiniboro; Thomas A Smith; Peter A Zimmerman; Peter Siba; Ivo Mueller; Ingrid Felger
Journal:  PLoS Negl Trop Dis       Date:  2011-12-20

8.  Diagnosis and Treatment of Plasmodium vivax Malaria.

Authors:  J Kevin Baird; Neena Valecha; Stephan Duparc; Nicholas J White; Ric N Price
Journal:  Am J Trop Med Hyg       Date:  2016-10-05       Impact factor: 2.345

9.  Efficacy of Pyrimethamine/Sulfadoxine versus Chloroquine for the Treatment of Uncomplicated Falciparum Malaria in Children Aged Under 5 Years.

Authors:  W Zheng; H Jiang; Z Xiong; Z Jiang; H Chen
Journal:  Iran J Parasitol       Date:  2013-01       Impact factor: 1.012

10.  Functional analysis of Plasmodium vivax dihydrofolate reductase-thymidylate synthase genes through stable transformation of Plasmodium falciparum.

Authors:  Alyson M Auliff; Bharath Balu; Nanhua Chen; Michael T O'Neil; Qin Cheng; John H Adams
Journal:  PLoS One       Date:  2012-07-09       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.